Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma

NCT00779714 is registered in ClinicalTrials.gov with University of Wuerzburg as lead sponsor.

NCT NCT00779714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma
Lead sponsor
University of Wuerzburg
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2008
Completion date
April 30, 2013
Enrollment
360 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma